Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate.

[1]  T E Schultheiss,et al.  Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. , 1999, The cancer journal from Scientific American.

[2]  P. Kupelian.  IMPROVEMENT IN OVERALL SURVIVAL FOR PATIENTS WITH LOCALIZED PROSTATE CANCER WITH HIGHER THAN STANDARD RADIATION DOSES: PRELIMINARY RESULTS , 1999 .

[3]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[4]  A. Pollack,et al.  Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. , 1998, Urology.

[5]  T E Schultheiss,et al.  Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.

[6]  A. Pollack,et al.  Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit? , 1998, Seminars in radiation oncology.

[7]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[8]  A. Pollack,et al.  External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? , 1998, Urology.

[9]  A. Pollack,et al.  External beam radiotherapy dose response of prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[10]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[11]  C J Moore,et al.  Predicting late rectal complications following prostate conformal radiotherapy using biologically effective doses and normalized dose-surface histograms. , 1997, The British journal of radiology.

[12]  E. Klein,et al.  Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. , 1997, International journal of radiation oncology, biology, physics.

[13]  D. Grignon,et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T E Schultheiss,et al.  Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. , 1996, International journal of radiation oncology, biology, physics.

[15]  G Starkschall,et al.  Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. , 1996, International journal of radiation oncology, biology, physics.

[16]  H. Sandler,et al.  Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. , 1995, International journal of radiation oncology, biology, physics.

[17]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[18]  A. Hanlon,et al.  Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. , 1997, International journal of radiation oncology, biology, physics.